New cell therapy aims to tame type 1 diabetes early
NCT ID NCT05626712
First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 27 times
Summary
This early-stage study tests a new treatment called CELZ-201 for people recently diagnosed with type 1 diabetes. The treatment is given through an artery and aims to see if it is safe and can help control the disease. The study involves 18 adults aged 18-35 who were diagnosed within the past year. The main goal is to check for side effects over 6 months, with follow-up up to 2 years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Diabetes Research Institute, University of Miami Miller School of Medicine
RECRUITINGMiami, Florida, 33136, United States
Contact Phone: •••-•••-••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.